吉非替尼治疗一例肺腺癌脑转移患者疗效分析
Analysis of the Efficacy of Gefitinib in the Treatment of Brain Metastases of Lung Adenocarcinoma
DOI: 10.12677/ACRPO.2018.73004, PDF, 下载: 1,438  浏览: 2,744  国家科技经费支持
作者: 白引苗, 陈 衍, 吴剑维, 孔胜男, 李新涛, 张红梅*：空军军医大学西京医院肿瘤科，陕西 西安
关键词: 吉非替尼；非小细胞肺癌；晚期肺癌；Gefitinib； Non-Small-Cell Lung Cancer； Advanced Lung Cancer
摘要: 肺癌是全球发病率以及死亡率最高的恶性肿瘤之一，其总的5年生存率约为17%。而非小细胞肺癌(non-small cell lung cancers, NSCLC)约占所有肺癌的85%~90%，大部分NSCLC患者确诊时已为晚期。吉非替尼为酪氨酸激酶抑制剂，美国综合肿瘤网络中心推荐其作为EGFR突变的肺腺癌患者的一线治疗方案。本文报道1例吉非替尼治疗晚期非鳞NSCLC脑转移患者。
Abstract: Lung cancer is one of the world’s most common and most malignant tumors. The five-year survival rate of is about 17%, non-small cell lung cancer (NSCLC) accounting for more than 85% - 90% of all cases. Most patients with NSCLC were diagnosed with advanced stage. Gefitinib is a tyrosine kinase inhibitor and is recommended as a first-line treatment for lung adenocarcinoma with EGFR mutation by the United States integrated tumor network center. This paper reports a case of gefitinib as a drug treatment in patient with advanced non-squamous NSCLC brain metastases.
文章引用：白引苗, 陈衍, 吴剑维, 孔胜男, 李新涛, 张红梅. 吉非替尼治疗一例肺腺癌脑转移患者疗效分析[J]. 亚洲肿瘤科病例研究, 2018, 7(3): 26-32. https://doi.org/10.12677/ACRPO.2018.73004

参考文献

[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30.
https://doi.org/10.3322/caac.21332
[2] Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132.
https://doi.org/10.3322/caac.21338
[3] Novello, S., Barlesi, F., Califano, R., et al. (2016) Metastatic Non-Small-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Fol-low-Up. Annals of Oncology, 27, v1-v27.
https://doi.org/10.1093/annonc/mdw326
[4] 梁宗锦, 徐子海, 周燕华. 肺癌脑转移瘤三维适形放疗和立体定向放疗疗效的比较分析[J]. 中国医疗设备, 2014, 29(10): 153-155.
[5] 罗晓飞. 吉非替尼联合放疗治疗肺癌脑转移瘤的疗效及不良反应情况探讨[J]. 基层医学论坛, 2017, 21(8): 1015-1016.
[6] 张帆. 肺癌脑转移瘤放疗方案的疗效比较及预后分析[J]. 临床医药文献电子杂志, 2016, 3(8): 1457, 1460.
[7] 陈景胜, 吴昱治, 陈光, 等. 吉非替尼联合放疗治疗肺癌脑转移瘤的临床研究[J]. 内科, 2015, 10(1): 38-40.
[8] Yan, D.F., Yan, S.X., Yang, J.S., et al. (2010) Hemorrhage of Brain Metastasis from Non-Small Cell Lung Cancer Post Gefitinib Therapy: Two Case Reports and Review of the Literature. BMC Cancer, 10, 49.
[9] 孙红梅, 陈文彰, 燕丽香, 等. 非小细胞肺癌脑转移瘤不同治疗方法的疗效评价以及预后分析[J]. 现代肿瘤医学, 2013, 21(3): 568-572.
[10] 张洪波, 张红雁, 罗文广, 等. 非小细胞肺癌脑转移瘤的放疗疗效评价及预后分析[J]. 蚌埠医学院学报, 2010, 35(7): 668-671.
[11] 董正, 范益民, 刘晓东, 等. 肺癌脑转移不同化疗药物联合全脑放疗治疗临床分析[J]. 中西医结合心脑血管病杂志, 2010, 8(10): 1263-1264.
[12] 孙红梅, 陈文彰, 燕丽香, 等. 60 例肺癌脑转移瘤患者生存与预后分析[J]. 临床肺科杂志, 2012, 17(7): 1273-1275.
[13] Wu, Y.L., Zhong, W.Z., Li, L.Y., et al. (2006) EGFR Mutations and the Correlation with Gefitinib Therapy in Chinese NSCLC—A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China. Journal of Clinical Oncology, 24, 7187.
[14] 吴一龙, 杨衿记, 林嘉颖, 等. 吉非替尼靶向治疗非小细胞肺癌的临床研究[J]. 中华结核和呼吸杂志, 2007, 30(2): 98-102.
[15] Rosell, R., Moran, T., Queralt, C., et al. (2009) Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. The New England Journal of Medicine, 361, 958-967.
https://doi.org/10.1056/NEJMoa0904554
[16] Gandara, D.R., Li, T., Lara, P.N., et al. (2014) Acquired Resistance to Targeted Therapies against Oncogene-Driven Non-Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implica-tions. Clinical Lung Cancer, 15, 1-6.
https://doi.org/10.1016/j.cllc.2013.10.001
[17] Yang, J.J., Chen, H.J., Yan, H.H., et al. (2013) Clinical Modes of EGFR Tyrosine Kinase Inhibitor Failure and Subsequent Management in Advanced Non-Small Cell Lung Cancer. Lung Cancer, 79, 33-39.
https://doi.org/10.1016/j.lungcan.2012.09.016